|

SUV2208A Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • Celest Therapeutics (Shanghai) Co., Ltd.1

Indications

  • CLDN18.2 Positive Solid Tumors1
  • Cancer1

Other1 trial

An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.